AI’s Next Healthcare Breakthrough Is Already Being Tested in Clinics June 30, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – For several generations now, the healthcare industry has been expensive, inefficient, and slow to change—however, several experts are seeing generative AI apps demonstrating real value in numerous ways. Beyond that, the next wave of the AI transformation of healthcare could come in the form of AI agents, diagnostics, and drug discovery. Behind the scenes, a number of forward-looking companies are making real advancements in the AI-in-healthcare space, including Avant Technologies, Inc. (OTCQB: AVAI), OptimizeRx Corporation (NASDAQ: OPRX), HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), Compugen Ltd. (NASDAQ: CGEN), and NVIDIA Corporation (NASDAQ: NVDA). According to ResearchAndMarkets, the AI in Medical Diagnostics Market is set to explode to $46.59 billion by 2034, growing at an exponential CAGR of 33.72%. Private equity investors say 2025 could outpace 2024 as one of the biggest years yet for AI-powere health tech. Recent private raises include Abridge raising $300 million for AI medical note-taking tech, Tennr clinching $101 million for AI that automates patient referrals, and $45 million was for Ellipsis Health and its “emotionally intelligent” AI healthcare. Meanwhile, in the public markets, several companies are moving beyond hype with real-world AI deployments already underway. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are preparing for a pivotal milestone: their pre-submission meeting with the U.S. FDA, scheduled for July 7. This session will shape the clinical pathway for Vision AI, the companies’ flagship disease-screening platform, as they seek 510(k) clearance for U.S. marketing approval—a move that could unlock major commercial potential. With experienced regulatory advisors and a global CRO, Fortrea, assisting in final preparations, the team is aiming for an efficient regulatory process that leads to large-scale diabetic screening capabilities across the U.S. “We’re approaching a key milestone,” said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio. “We’ve been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we’re optimistic about the outcome. Diabetic retinopathy is the number one cause of preventable blindness worldwide. That’s unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer’s, cardiovascular disease, and more.” Avant’s broader diabetes push is now entering a critical phase. It has signaled intentions to launch a standalone company to develop a potential treatment for diabetes, complementing its screening and detection suite. This would streamline its structure by integrating data, IP, and leadership under one roof, eliminating the holding-company inefficiencies currently in place. Over 30% of those living with diabetes will develop diabetic retinopathy, a disease that can be prevented with an accurate diagnosis. More recently, Avant and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka’s Fischel and La Bomba pharmacy chains. Avant’s Vision AI platform uses retinal imaging and artificial intelligence to rapidly detect diabetic retinopathy and other retinal diseases, as well as systemic conditions like fatty liver, chronic kidney disease, and cardiovascular risk. The team is finalizing a low-cost, cloud-connected retinal camera that could operate in clinics and rural settings without specialist staff. And with new disease modules in the pipeline—including a blood test-linked dementia screening tool—Avant is steadily building out a scalable, multi-condition platform designed to close the loop between early detection and timely intervention. “We’re committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world,” added Vargas. “That’s the mission behind everything we do.” Recently, Avant signed a non-binding letter of intent to acquire 100% of Ainnova Tech—bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ OptimizeRx Corporation (NASDAQ: OPRX) is expanding its AI-driven healthcare engagement strategy through a new partnership with Simulmedia, bringing clinically targeted Micro-Neighborhood audiences to TV and streaming platforms. "This partnership extends the reach of Micro-Neighborhood Targeting into high-impact TV environments," said Steve Silvestro, CEO of OptimizeRx. "It offers a scalable, clinically-driven alternative – or augmentation – to traditional ‘spray-and-pray’ TV campaigns—especially valuable for brands prioritizing omnichannel impact." The platform blends geographic disease prevalence, real-world clinical data, and predictive modeling to deliver smarter, privacy-compliant outreach to patients. This AI-powered expansion enables life sciences brands to engage patients more precisely—on screen, at home, and across the full healthcare journey. HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) is making a major push into the U.S. healthcare market by launching a suite of AI-powered tools alongside the data infrastructure platform of its newly acquired partner, Orion Health. "Orion has had a material presence in the USA for over two decades," said Brad Porter, Chief Commercial Officer at HEALWELL. "We now have a unique opportunity to accelerate value for our customers by combining Orion's trusted platform with HEALWELL's next-generation AI capabilities. The robust clinical validation and data lineage features differentiates these tools in the market and ultimately reduces friction with regards to clinical adoption." The strategy centers on embedding AI for clinical search, summarization, and risk stratification directly into existing U.S. health systems, enabling scalable, real-time insights without disrupting workflows. This move gives HEALWELL instant access to a market valued at over $160 billion—and growing rapidly. Compugen Ltd. (NASDAQ: CGEN) is advancing the role of AI and machine learning in cancer immunotherapy with new computational research being presented at major international conferences. The company’s predictive platform is being used to map tumor subtypes in triple-negative breast cancer (TNBC), helping to uncover mechanisms of immune evasion and resistance to immunotherapy. This AI-driven discovery work supports the development of more targeted treatment strategies and is integrated with Compugen’s broader immuno-oncology pipeline. As a pioneer in computational biology, Compugen continues to translate data into drug targets with first-in-class potential across solid tumors. NVIDIA Corporation’s (NASDAQ: NVDA) cutting-edge HGX B200 cluster is now powering the next phase of Iambic Therapeutics’ AI drug discovery platform, Enchant v2—an advanced model for predicting molecular properties. Iambic is using the NVIDIA-backed infrastructure via Lambda’s GPU cloud to accelerate development of new medicines with improved safety, efficacy, and trial-readiness. The model has shown potential to outperform traditional in vitro testing for drug clearance, offering a breakthrough in in silico prediction accuracy. As more biotech firms turn to transformer-based AI models, NVIDIA’s role at the computational core of this shift continues to expand. Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: Baystreet.ca [email protected] (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. [JC1]Please insert hyperlink to new PR link here when it comes out.
AI’s Next Healthcare Breakthrough Is Already Being Tested in Clinics June 30, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – For several generations now, the healthcare industry has been expensive, inefficient, and slow to change—however, several experts are seeing generative AI apps demonstrating real value in numerous ways. Beyond that, the next wave of the AI transformation of healthcare could come in the form of AI agents, diagnostics, and drug discovery. Behind the scenes, a number of forward-looking companies are making real advancements in the AI-in-healthcare space, including Avant Technologies, Inc. (OTCQB: AVAI), OptimizeRx Corporation (NASDAQ: OPRX), HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), Compugen Ltd. (NASDAQ: CGEN), and NVIDIA Corporation (NASDAQ: NVDA). According to ResearchAndMarkets, the AI in Medical Diagnostics Market is set to explode to $46.59 billion by 2034, growing at an exponential CAGR of 33.72%. Private equity investors say 2025 could outpace 2024 as one of the biggest years yet for AI-powere health tech. Recent private raises include Abridge raising $300 million for AI medical note-taking tech, Tennr clinching $101 million for AI that automates patient referrals, and $45 million was for Ellipsis Health and its “emotionally intelligent” AI healthcare. Meanwhile, in the public markets, several companies are moving beyond hype with real-world AI deployments already underway. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are preparing for a pivotal milestone: their pre-submission meeting with the U.S. FDA, scheduled for July 7. This session will shape the clinical pathway for Vision AI, the companies’ flagship disease-screening platform, as they seek 510(k) clearance for U.S. marketing approval—a move that could unlock major commercial potential. With experienced regulatory advisors and a global CRO, Fortrea, assisting in final preparations, the team is aiming for an efficient regulatory process that leads to large-scale diabetic screening capabilities across the U.S. “We’re approaching a key milestone,” said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio. “We’ve been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we’re optimistic about the outcome. Diabetic retinopathy is the number one cause of preventable blindness worldwide. That’s unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer’s, cardiovascular disease, and more.” Avant’s broader diabetes push is now entering a critical phase. It has signaled intentions to launch a standalone company to develop a potential treatment for diabetes, complementing its screening and detection suite. This would streamline its structure by integrating data, IP, and leadership under one roof, eliminating the holding-company inefficiencies currently in place. Over 30% of those living with diabetes will develop diabetic retinopathy, a disease that can be prevented with an accurate diagnosis. More recently, Avant and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka’s Fischel and La Bomba pharmacy chains. Avant’s Vision AI platform uses retinal imaging and artificial intelligence to rapidly detect diabetic retinopathy and other retinal diseases, as well as systemic conditions like fatty liver, chronic kidney disease, and cardiovascular risk. The team is finalizing a low-cost, cloud-connected retinal camera that could operate in clinics and rural settings without specialist staff. And with new disease modules in the pipeline—including a blood test-linked dementia screening tool—Avant is steadily building out a scalable, multi-condition platform designed to close the loop between early detection and timely intervention. “We’re committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world,” added Vargas. “That’s the mission behind everything we do.” Recently, Avant signed a non-binding letter of intent to acquire 100% of Ainnova Tech—bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ OptimizeRx Corporation (NASDAQ: OPRX) is expanding its AI-driven healthcare engagement strategy through a new partnership with Simulmedia, bringing clinically targeted Micro-Neighborhood audiences to TV and streaming platforms. "This partnership extends the reach of Micro-Neighborhood Targeting into high-impact TV environments," said Steve Silvestro, CEO of OptimizeRx. "It offers a scalable, clinically-driven alternative – or augmentation – to traditional ‘spray-and-pray’ TV campaigns—especially valuable for brands prioritizing omnichannel impact." The platform blends geographic disease prevalence, real-world clinical data, and predictive modeling to deliver smarter, privacy-compliant outreach to patients. This AI-powered expansion enables life sciences brands to engage patients more precisely—on screen, at home, and across the full healthcare journey. HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) is making a major push into the U.S. healthcare market by launching a suite of AI-powered tools alongside the data infrastructure platform of its newly acquired partner, Orion Health. "Orion has had a material presence in the USA for over two decades," said Brad Porter, Chief Commercial Officer at HEALWELL. "We now have a unique opportunity to accelerate value for our customers by combining Orion's trusted platform with HEALWELL's next-generation AI capabilities. The robust clinical validation and data lineage features differentiates these tools in the market and ultimately reduces friction with regards to clinical adoption." The strategy centers on embedding AI for clinical search, summarization, and risk stratification directly into existing U.S. health systems, enabling scalable, real-time insights without disrupting workflows. This move gives HEALWELL instant access to a market valued at over $160 billion—and growing rapidly. Compugen Ltd. (NASDAQ: CGEN) is advancing the role of AI and machine learning in cancer immunotherapy with new computational research being presented at major international conferences. The company’s predictive platform is being used to map tumor subtypes in triple-negative breast cancer (TNBC), helping to uncover mechanisms of immune evasion and resistance to immunotherapy. This AI-driven discovery work supports the development of more targeted treatment strategies and is integrated with Compugen’s broader immuno-oncology pipeline. As a pioneer in computational biology, Compugen continues to translate data into drug targets with first-in-class potential across solid tumors. NVIDIA Corporation’s (NASDAQ: NVDA) cutting-edge HGX B200 cluster is now powering the next phase of Iambic Therapeutics’ AI drug discovery platform, Enchant v2—an advanced model for predicting molecular properties. Iambic is using the NVIDIA-backed infrastructure via Lambda’s GPU cloud to accelerate development of new medicines with improved safety, efficacy, and trial-readiness. The model has shown potential to outperform traditional in vitro testing for drug clearance, offering a breakthrough in in silico prediction accuracy. As more biotech firms turn to transformer-based AI models, NVIDIA’s role at the computational core of this shift continues to expand. Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: Baystreet.ca [email protected] (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. [JC1]Please insert hyperlink to new PR link here when it comes out.